Business Wire

Nearly Three Quarters of U.S. Travellers Support the Introduction of International Vaccine Passports, According to OAG Research

13.9.2021 16:00:00 EEST | Business Wire | Press release

Share

Travellers are taking to the skies again, but the immediate future of air travel remains highly turbulent, according to OAG’s survey of 1,800-plus U.S. travellers in July and August. Domestic capacity in the U.S. is up 81% from June – August 2021, compared to the same period last year. The increase is being fuelled by strong consumer demand; 70% of consumers surveyed by OAG have booked flights for the future.

While travellers’ willingness to fly is increasing, the Delta variant, increased COVID transmission rates and vaccination preferences weigh heavily on the near and mid-term outlook. The large majority of consumers surveyed by OAG report being fully vaccinated. However, OAG found that only 15% of non-vaccinated individuals plan to get vaccinated before their next trip.

Many airlines and destinations are considering vaccine mandates to strengthen confidence and fight transmission. Sixty-eight percent of all survey respondents said they are interested in or want domestic vaccine passports, and 70% believe vaccine passports should be required for international travel. Alarmingly, of those that said they were not yet vaccinated, 56% said they still wouldn’t get vaccinated even if the airline, airport, or destination required it to travel.

“Vaccine mandates are a polarizing issue. Many airlines, governments and destinations are actively considering mandating vaccines to fly or enter, and the majority of travellers support the use of vaccine passports,” said John Grant, senior analyst at OAG. “While this may add fuel to hot fire, the ongoing strength and resilience of the entire travel market is directly linked to higher vaccination levels and lower transmission rates.”

Other takeaways from OAG’s research include:

  • Continued COVID-19 concerns keep some travellers grounded. Of the 30% of respondents who haven’t booked flights yet, 40% are waiting for vaccination rates and regulations to improve and 30% are waiting for vaccine passports to be required.
  • The business travel outlook remains cloudy. Only 62% of business travellers said their company is planning air travel in the next 12 months, while 38% said their company either has no plans (20%) or has not specified plans (18%).
  • Holiday travel expected to bounce back. The 2021 holiday travel season projects to be a lot stronger than 2020. Of the 38% of travellers surveyed by OAG that said they typically fly for the holidays, only 40% of this group did so in 2020. This year, the percentage of that group who do intend to fly more than doubled (85%). Planned capacity for Thanksgiving week tells a similar story, currently with 47% more domestic seats booked than last year.
  • Booking behaviour remains erratic. Nearly half of travellers surveyed are still booking on short notice (between two weeks to a month in advance), and half are booking between two-six-plus months out. Eighty-eight percent expect ticket prices to rise in the next 12 months.

For the full survey insights, view the report here, https://www.oag.com/us-traveler-survey. To learn more about OAG, visit https://www.oag.com/.

About OAG

OAG is a leading global travel data provider, that has been powering the growth and innovation of the air travel ecosystem since 1929. Headquartered in the UK, OAG has global operations in the USA, Singapore, Japan, Lithuania and China. For more information, visit: www.oag.com and follow us on Twitter @OAG Aviation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chrissy Azevedo
Corporate Ink for OAG
pressoffice@oag.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 22:50:00 EET | Press release

Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme

REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 16:38:00 EET | Press release

Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net profit was at €250.9 million. In 2024, the corresponding value was €211.1 million. Following the results achieved in 2025, the Reply Board of Directors decided to propose to the next Shareholders’ Meeting a dividend distribution of €1.35 per share, which will be payable on 20 May 2026, with dividend date set on 18 May 2026 (record

LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 15:51:00 EET | Press release

LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t

Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 15:30:00 EET | Press release

Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and collaborations with leading pharmaceutical companies, including MSD since 2023 for MSIntuit, Waiv is establishing itself as a leader in translational medical AI. Waiv leverages a decade of Owkin's foundational medical AI research, including access to an extensive patient data net

RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 15:30:00 EET | Press release

RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that helps sponsors gain earlier clarity, reduce risk, and execute complex programs

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye